Effects of omeprazole and genetic polymorphism of CYP2C19 on the clopidogrel active metabolite.

Clopidogrel is an antiplatelet agent widely used in cardiovascular diseases and an inactive prodrug that needs to be converted to an active metabolite in two sequential metabolic steps. Several CYP450 isoforms involved in these two steps have been described, although the relative contribution in vivo of each enzyme is still under debate. CYP2C19 is considered […]

Read More
Learn More